IL6R and neoplasm: Surprisingly, in shMCT-1 circumstances, sequential immunotherapy (anti-PD-L1 → anti-IL-6R) successfully prevented tumor relapse (0%) and metastasis (28.5%), achieved a disease-free survival advantage (100%) (Figure 5J) and diminished the recurrent tumor loads (Figure 5K).